- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Father of Evidence-Based Medicine, Dr Sackett, Passes Away
In his own words, "The practice of evidence-based medicine means integrating individual clinical expertise with the best available external clinical evidence from systematic research."
The key thing that differentiates modern medicine from the healing arts of the past is its embrace of science. And few people did more to advance that cause than David Sackett.
Sackett, who died on Wednesday at the age of 80, was widely known as the father of the "evidence-based medicine" movement—arguably one of the most important recent advances in medical practice.
Many people might wonder, "Wasn't medicine always evidence-based?" Not necessarily. Until researchers like Sackett started to push the profession in a more scientific direction in the 1990s, a surprising amount of medical practice was simply rooted in expert opinion and whatever doctors learned in medical school — not the best or most up-to-date knowledge. But then came "evidence-based medicine.
Complete report on Vox: http://bit.ly/1GcXv3A
Clinical Characteristics, Outcomes of Patients With Plaque Psoriasis on Tapinarof Cream
December 5th 2023Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinerof cream.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More
